OD Expert Group’s Post

Last week, as President of Medicines for Europe I had the chance to participate in one of the panels of the High-level Conference on the Future EU Health Union. I am very impressed by the priority the Belgian Presidency of the EU Council is giving to Health, this is important for Europe, for the European patients and for the European industry. We had a very interesting discussion on the Voluntary Solidarity Mechanism and the EU Stockpiling Strategy. Did you know that the compulsory stockpiling of 6 months currently applicable in Germany for certain antibiotics equals the annual consumption of 10 Member States? How can we work together and coordinate for equal and on-time access for all European patients? #EU2024BE #genericmedicines #europe #medicinesforeurope

Key achievements: - Stronger health security measures, to better prepare for and respond to future crises - Equal and timely access to affordable medicines for all citizens thanks to the proposed reform of the EU pharmaceutical legislation - A world-leading Cancer Plan, backed by €4 billion in EU funding - Game-changing initiatives to digitalise healthcare - Comprehensive actions for better mental health, from promoting mental wellbeing, to improving prevention and support services - Rules to boost patient safety and secure the supply of medicinal products - A One Health approach to tackle major health risks

The European Commission's public consultation on the Health Technology Assessment Implementing Act, focusing on cooperation with the European Medicines Agency. This is crucial for streamlined and efficient assessment of new health technologies in the EU. Contribute your thoughts by July 24, 2024. #EUHealthPolicy #HealthTech #PublicConsultation

The World Health Assembly session to decide on the Global Pandemic Treaty concluded on 01 June 2024 without an agreement due to inability to decide on the provisions of the Pathogen Access and Benefit Sharing (PABS) system. This is unfortunate. While everyone agrees on the principle of #fair and #equity based sharing of benefits arising from the use of resources and associated knowledge, the operationalization of these principles are always addressed differently by different sectors of stakeholders. Experiences from the negotiations and implementation of the Convention on Biological Diversity (CBD) Nagoya Protocol on Access and Benefit Sharing (ABS) will come handy to move forward the negotiations. With an extended timeline of one more year to conclude the negotiations, the World Health Assembly needs renewed efforts to bring different interests on access and benefit sharing together to the table and agree on the PABS with full and informed participation of all relevant stakeholders.  #fairness #equity #access #benefitsharing #pandemic #priorinformedconsent #pandemicpreparedness #commercialbenefits

Let's strategize accordingly:

Patients in the EU should always have access to the medicines they need.    Today, we are taking steps to set up a Critical Medicines Alliance to secure medicines with the highest risk of shortages and impact on healthcare systems.     We are calling national authorities, the industry, and civil society to express their interest and join in our efforts to:     🤝 explore the diversification of global supply chains;  🧪 boost Europe's capacity to boost manufacturing of critical medicines;  📦 develop a common strategic approach to medicines stockpiling;  ⏩ and more.     European public health has been and continues to be our priority in our actions.     The Critical Medicine Alliance adds an industrial policy pillar to our European Health Union ensuring patients are better protected and always have access to the medicines they need.    Discover more ➡ https://lnkd.in/e8EHN79b    #HealthUnion 

🏆 Council conclusions on the Future of the European Health Union: A Europe that cares, prepares and protects ⭐⭐⭐Council of the European Union ✔The rapid evolution of 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 impacts healthcare systems. The acceleration of 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝘁𝗼𝗼𝗹𝘀 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝘁𝗲𝗹𝗲𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲, 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲𝘀 𝘀𝗼𝗳𝘁𝘄𝗮𝗿𝗲 𝗮𝗻𝗱 𝗿𝗲𝗺𝗼𝘁𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴, as well as digital self-diagnosis, have the potential to improve patient outcomes and enhance healthcare accessibility. At the same time, technological advancements, such as 𝗔𝗿𝘁𝗶𝗳𝗶𝗰𝗶𝗮𝗹 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲, provide opportunities for research, policy making, gathering and using real world data, the development of 𝗻𝗲𝘄 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀 𝗮𝗻𝗱 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲𝘀, 𝗮𝗻𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗽𝘂𝗯𝗹𝗶𝗰 𝗵𝗲𝗮𝗹𝘁𝗵, but also introduce complex ethical and societal challenges that requires coordinated action at national, European and international levels. ✔𝗛𝗲𝗮𝗹𝘁𝗵 𝗱𝗮𝘁𝗮 𝗽𝗹𝗮𝘆 𝗮 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝗿𝗼𝗹𝗲 𝗶𝗻 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗶𝗻𝗱𝗶𝘃𝗶𝗱𝘂𝗮𝗹 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗮𝗿𝗲, 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝗮𝗻𝗱 𝘀𝗵𝗮𝗽𝗶𝗻𝗴 𝗽𝘂𝗯𝗹𝗶𝗰 𝗵𝗲𝗮𝗹𝘁𝗵 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀. It is fundamental that citizens have the transparency over the use of their personal health information, ensuring protection and security, as well as raising awareness to foster trust and encourage data sharing for the greater good. The benefits of utilising health data in line with European values and patients’ data protection rules for society are immense, including the 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗳𝗼𝗿 𝗲𝗮𝗿𝗹𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻, 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗮𝗻𝗱 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀. 💕Take a look at the article "Smart Hospital: The AI Wave of Digital Transformation" https://lnkd.in/dh-mB2D3 #DigitalTransformation, #SmartHospital, #SmartClinic, #PatientCentered, #ValueBased, #DigitalFirst, #AIEnabled, #TechnologyAdvanced, #HyperConnected, #AI

The Italian Medicines Agency (AIFA) reform finally went live January 30 and the restructuring impacts the agency's governing bodies and top management structure. The impact of these changes on the Italian healthcare system and its stakeholders, as well as how the new AIFA will align with the anticipated new European health policies, is still uncertain. ▶ Click through for three key changes introduced in this restructuring, and connect with Giovanni Firenze, MSE, MBA, Partner, Consulting Italy, to discuss further. #aifa

Collaboration with focus on the changes in the EU pharmaceutical regulation

🚀 Exciting times in the world of medicine! The European Medicines Agency (EMA) is embracing transformative changes in the landscape of healthcare. With new technologies and innovative approaches, they are seizing opportunities to enhance patient care and streamline drug development. Use the opportunity to provide feedback until 30-Nov-2024. 🌟 From cutting-edge therapies to personalized medicine, the future looks bright! Join to explore how these advancements will shape health outcomes for all. 👉 Read more about these pivotal changes and their impact on the healthcare landscape: https://lnkd.in/dUbZSrJ9 #HealthInnovation #PatientCare #EMA #FutureOfMedicine